GSK-J1 lithium salt is a potent inhibitor of me2-demethylases JMJD3/H3K27me3/KDM6B and UTX/KDM6A (IC50: 60 nM towards KDM6B).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | Inquiry | $ 98 | |
20 mg | Inquiry | $ 186 | |
40 mg | Inquiry | $ 281 | |
100 mg | Inquiry | $ 522 | |
200 mg | Inquiry | $ 835 |
Description | GSK-J1 lithium salt is a potent inhibitor of me2-demethylases JMJD3/H3K27me3/KDM6B and UTX/KDM6A (IC50: 60 nM towards KDM6B). |
Targets&IC50 | KDM6B:60 nM |
In vitro | GSK-J1 inhibits TNF-α production by human primary macrophages in an H3K27-dependent manner.?GSK-J1 inhibits the demethylase activity of KDM5C with 8.5-fold increased potency compared with that of KDM5B at 1 mM α-ketoglutarate, with IC50 of 11 μM and 94 μM, respectively.GSK-J1 is selective for H3K27 demethylases of the KDM6 subfamily and specifically binds to endogenous JMJD3. |
Chemical Formula | C22H22LiN5O2 |
Molecular Weight | 395.38 |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom